Thomas Gad | Founder, President, Interim Chief Executive Officer |
Sue Smith | Senior Vice President and Chief Commercial Officer |
Vignesh Rajah | Senior Vice President and Chief Medical Officer |
Bo Kruse | Chief Financial Officer, Treasurer, and Secretary |
William Maughan | Canaccord Genuity |
Mike Ulz | Morgan Stanley |
Charles Zhu | Guggenheim Securities |
Tessa Romero | JP Morgan |
David Nierengarten | Wedbush Securities |
Good morning, and welcome to the Y-mAbs Therapeutics, Inc.'s Earnings Call for the First Quarter of 2023. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time.
As reminder, today's conference is being recorded.
Let me quickly remind you that the following discussion contains certain statements that are considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995.